Production (Stage)
ImmunityBio, Inc.
IBRX
$3.44
$0.299.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10,051.99% | 2,181.35% | 1,181.12% | 111.32% | -48.46% |
| Total Other Revenue | 86.42% | 127.10% | 215.45% | 675.61% | -- |
| Total Revenue | 10,238.41% | 2,270.58% | 1,218.71% | 120.95% | -48.46% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 10,219.21% | 2,270.58% | 1,218.71% | 120.95% | -48.46% |
| SG&A Expenses | 13.83% | 28.07% | 27.35% | 37.62% | 44.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.19% | -0.84% | 1.36% | -3.20% | -5.88% |
| Operating Income | 9.15% | 4.75% | 0.51% | 3.40% | 5.81% |
| Income Before Tax | 31.93% | 29.16% | -28.16% | -26.05% | -39.59% |
| Income Tax Expenses | -485.00% | -- | -217.65% | -217.65% | -217.65% |
| Earnings from Continuing Operations | 31.96% | 29.15% | -28.14% | -26.04% | -39.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -81.69% | -87.65% | -88.46% | -86.45% | -46.77% |
| Net Income | 31.93% | 29.09% | -28.33% | -26.25% | -39.73% |
| EBIT | 9.15% | 4.75% | 0.51% | 3.40% | 5.81% |
| EBITDA | 9.19% | 4.73% | 0.19% | 3.30% | 6.00% |
| EPS Basic | 47.69% | 46.85% | 17.17% | 17.36% | -0.02% |
| Normalized Basic EPS | 47.55% | 46.70% | 15.83% | 16.13% | -2.07% |
| EPS Diluted | 44.56% | 43.83% | 14.98% | 17.13% | -0.71% |
| Normalized Diluted EPS | 47.59% | 46.74% | 15.86% | 16.13% | -2.07% |
| Average Basic Shares Outstanding | 30.33% | 37.13% | 54.15% | 51.40% | 39.76% |
| Average Diluted Shares Outstanding | 30.48% | 37.30% | 54.27% | 51.40% | 39.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |